A Multi-Center, Adaptive Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled (Sitagliptin), Parallel Group Study to Evaluate the Safety and Efficacy of TTP399 Following 6 Months Administration in Subjects With Type 2 Diabetes Mellitus on A Stable Dose of Metformin
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Cadisegliatin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms AGATA
- Sponsors vTv Therapeutics LLC.
- 16 Jan 2019 According to a vTv Therapeutics LLC media release, Dr. Adrian Vella, Professor of Medicine at the Mayo Clinic is a principle investigator for the study.
- 16 Jan 2019 According to a vTv Therapeutics LLC media release, data from the study is published in the latest edition of the peer-reviewed journal Science Translational Medicine.
- 16 Jan 2019 Results presented in a vTv Therapeutics LLC media release.